Page 39 - CIBEREHD2016-ENG

Most relevant scientific articles
• Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J et al. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis.Gastroenterology. 2016;150(5).
• Villanueva C., Albillos A., Genesca J., Abraldes J.G., Calleja J.L., Aracil C. et al. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension. Hepatology. 2016;63(1):197-206.
• Berzigotti A, Albillos A, Villanueva C, Genescá J, Ardevol A, Augustín S et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The sportdiet study.Hepatology (Baltimore, Md.). 2016.
• Bissonnette J., Carlos Garcia-Pagan J., Albillos A., Turon F., Ferreira C., Tellez L. et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology. 2016.
• Albillos A., Martinez J.. Prognostic value of bacterial infection in acute and chronic liver failure. Liver International. 2016;36(8):1090-1092.
Hightlights
During the year 2016 the University of Alcalá-Ramón y Cajal University Hospital group has worked on projects aimed at modulating the damage of the intestinal barrier in rats with cirrhosis and reducing the high rate of bacterial translocation observed in this model. In relation to the clinical projects we have studied the alterations of the T lymphocyte compartment in patients with chronic liver disease by alcohol and virus C, and the modifications in the latter compartment after the antiviral treatment. With regard to clinical projects we have participated in different cooperative studies including the analysis of changes
in cardiac function during beta-blocker treatment in advanced cirrhosis, the clinical trial to evaluate the efficacy of rivaroxaban in the natural history of cirrhosis And the efficacy of the methacetin breath test to identify patients with significant portal hypertension and follow-up of those treated with antivirals and portal pressure gradient response in patients with C virus cirrhosis on antiviral therapy. In addition, we have worked with regulatory agencies in the trial to study the efficacy of rivaroxaban in the natural history of cirrhosis with portal venous thrombosis. Alongside this, our group has participated in national cooperative studies describing the extensive experience accumulated in Spain on the use of direct-acting antivirals and in clinical trials using different drugs against fatty liver disease. We have contributed to national guidelines for hepatic vascular disease.
EHD
research Groups 39